Liver disease and malignant ascites

Published & Presented studies
Ongoing studies
Other alfapump publications
RETROSPECTIVE MALIGNANT ASCITES STUDY

Retrospective, multi-centre, open-label study in Europe to assess the performance and safety of the alfapump® in 17 patients with malignant ascites (NCT03200106).

Abstract | Poster by Fotopoulou et al., IGCS, 2018


MOSAIC IDE FEASIBILITY STUDY

Prospective, multi-centre, open-label, single-arm study in North America to assess the safety and efficacy of the alfapump® in 30 patients with liver recurrent or refractory ascites not eligible for TIPS (NCT02400164).

Abstract | Poster par Wong et al., AASLD, 2017
Poster by Wong et al., AASLD, 2018


HANNOVER STUDY
Retrospective, single-centre study at Hannover Medical School to investigate the alfapump® as an alternative for LVP in 21 patients with liver refractory ascites with a contraindication for TIPS or liver transplant.

Solbach et al., European Journal of Gasteroenterology & Hepatology, 2018


PMSR
Prospective, multi-centre, open-label, observational study in Europe designed to follow 100 patients with liver refractory ascites with a contra-indication to TIPS and therefore treated with an alfapump® for up to 24 months (NCT01532427).

Stirnimann et al., Alimentary Pharmacology & Therapeutics, 2017 (data on the first 56 patients)
Editorial by Macdonald and Jalan, Alimentary Pharmacology & Therapeutics, 2017


RCT
Prospective, multi-centre, open-label, randomised and controlled study in Europe of the alfapump® versus LVP standard of care in 58 patients with liver refractory ascites (NCT01528410).

Bureau et al., Journal of Hepatology, 2017
Stepanova et al., Quality of Life Research, 2017


PIONEER STUDY
Prospective, multi-centre, open-label, uncontrolled study in Europe to assess the safety and performance of the alfapump® in 40 patients with liver refractory ascites and diuretic resistance (NCT01030185).

Bellot et al., Journal of Hepatology, 2013

POSEIDON STUDY

This is a single-arm, open-label, within subject crossover study of the alfapump® in patients with recurrent or refractory ascites due to liver cirrhosis in centres across the U.S. and Canada. Up to 60 patients will be enrolled in the study, entering into the pre-implant observation period, allowing for up to 50 patients to be implanted with the alfapump® for primary endpoint analysis. The study also allows for up to 30 patients to be enrolled in a training cohort, to ensure centres are experienced with the alfapump® prior to enrolment in the pivotal study cohort.

Pivotal cohort patients will enter into a 3-month pre-implant observation period in which they will receive standard of care therapy (consisting of paracentesis) before the alfapump® is implanted. The primary effectiveness outcomes of the study include the proportion of patients with a 50% reduction in the overall average frequency of therapeutic paracentesis per month in the post-implant observation period (month four to month six after implantation) as compared to the pre-implant observation period. The primary safety endpoint is the rate of alfapump® related re-interventions adjudicated by the Clinical Events Committee. Patients will be followed for up to two years for analysis of secondary outcome measurements including safety (device and/or procedure-related adverse events), quality of life (assessed by general SF-36 as well as disease-specific Ascites-Q questionnaires), patients’ nutritional status, health economics and overall survival. For more information about the study, please visit clinicaltrials.gov (NCT03973866).

ARIA pump STUDY

This is a prospective, multi-centre, open-label, randomised, health-economic study in France to evaluate the cost utility of the alfapump® versus standard of care in 90 patients with liver refractory ascites, 60 patients not waiting for liver transplant and 30 patients as bridge to transplant, over 12 months. The goal of the study is to support French reimbursement. The study is funded by the French government and being conducted and sponsored by leading French clinicians (NCT03506893).

TOPMOST REGISTRY

This is a European registry to collect data from prospectively enrolled patients that have been implanted with the alfapump® across commerical centres in Europe. The registry is supported by key opinion leaders and will assess the adverse event profile of the alfapump® following the technical improvements in product design and care protocols, as well as the effectiveness in real world circumstances. Patients are being enrolled on a continual basis and interim readouts will take place at regular time points.

Case study of treatment of a patient with malignant ascites using the alfapump®.

Storni et al., The American Journal of Gastroenterology, 2018


Review of the available data about patient selection, efficacy and safety of the alfapump® and recommendations for the management of patients treated with the alfapump®.

Stirnimann et al., Therapeutics Advances in Gastroenterology, 2017

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our
Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close